Furthermore, the administration of lung cancer cells with GSK343, a well-established EZH2 inhibitor, led to a significant reduction in cellular motility and migration, indicating a functional relevance of EZH2 in our system (Supplementary Figure S2). This evidence concerns the gene EZH2 and lung cancer.